

7.5% SODIUM BICARBONATE- 7.5% sodium bicarbonate injection, solution
PEDIATRIC 8.4% SODIUM BICARBONATE- pediatric 8.4% sodium bicarbonate injection, solution
HF Acquisition Co LLC, DBA HealthFirst

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click [here](#).

SODIUM BICARBONATE INJECTION

SPL UNCLASSIFIED

FOR CORRECTION OF METABOLIC ACIDOSIS AND
OTHER CONDITIONS REQUIRING SYSTEMIC ALKALINIZATION.

Abboject® Syringe

LVP Glass Container

Fliptop Vial

DESCRIPTION

Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO_3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer.

Solutions are offered in concentrations of 4.2%, 5.0%, 7.5% and 8.4%. See table in HOW SUPPLIED section for contents and characteristics.

Solution in LVP container has 0.9 mg/mL of edetate disodium, anhydrous added as a stabilizer.

The solutions contain no bacteriostat, antimicrobial agent or added buffer and are intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.

Sodium bicarbonate, 84 mg is equal to one milliequivalent each of Na^+ and HCO_3^- . Sodium Bicarbonate, USP is chemically designated NaHCO_3 , a white crystalline powder soluble in water.

Water for Injection, USP is chemically designated H_2O .

CLINICAL PHARMACOLOGY

Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

Sodium bicarbonate in water dissociates to provide sodium (Na^+) and bicarbonate (HCO_3^-) ions. Sodium (Na^+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Bicarbonate (HCO_3^-) is a normal constituent of body fluids and the normal plasma level ranges from 24 to 31 mEq/liter. Plasma concentration is regulated by the kidney through acidification of the urine when there is a deficit or by alkalization of the urine when there is an excess. Bicarbonate anion is considered "labile" since at a proper concentration of hydrogen ion (H^+) it may be converted to carbonic acid (H_2CO_3) and thence to its volatile form, carbon dioxide (CO_2) excreted by the lung. Normally a ratio of 1:20 (carbonic acid: bicarbonate) is present in the extracellular fluid. In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% is excreted in the urine.

INDICATIONS & USAGE

Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.

Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis — e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself.

Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO₂ content is crucial — e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis.

CONTRAINDICATIONS

Sodium Bicarbonate Injection, USP is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction, and in patients receiving diuretics known to produce a hypochloremic alkalosis.

WARNINGS

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Extravascular infiltration should be avoided, see ADVERSE REACTIONS.

PRECAUTIONS

The potentially large loads of sodium given with bicarbonate require that caution be exercised in the use of sodium bicarbonate in patients with congestive heart failure or other edematous or sodium-retaining states, as well as in patients with oliguria or anuria. See table in HOW SUPPLIED section for amounts of sodium present in solutions.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Potassium depletion may predispose to metabolic alkalosis and coexistent hypocalcemia may be associated with carpopedal spasms as the plasma pH rises. These dangers can be minimized if such electrolyte imbalances are appropriately treated prior to or concomitantly with bicarbonate infusion.

Rapid injection (10 mL/min) of hypertonic Sodium Bicarbonate Injection, USP, solutions into neonates and children under two years of age may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible intracranial hemorrhage. The rate of administration in such patients should

therefore be limited to no more than 8 mEq/kg/day. A 4.2% solution may be preferred for such slow administration. In emergencies such as cardiac arrest, the risk of rapid infusion must be weighed against the potential for fatality due to acidosis.

Drug Interactions

Additives may be incompatible; norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.

The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. Precipitation or haze may result from sodium bicarbonate-calcium admixtures. NOTE: Do not use the injection if it contains precipitate.

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Laboratory Tests

The aim of all bicarbonate therapy is to produce a substantial correction of the low total CO₂ content and blood pH, but the risks of overdosage and alkalosis should be avoided. Hence, repeated fractional doses and periodic monitoring by appropriate laboratory tests are recommended to minimize the possibility of overdosage.

Pregnancy Category C. Animal reproduction studies have not been conducted with sodium bicarbonate. It is also not known whether sodium bicarbonate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium bicarbonate should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS

Overly aggressive therapy with Sodium Bicarbonate Injection, USP can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia.

Inadvertent extravasation of intravenously administered hypertonic solutions of sodium bicarbonate have been reported to cause chemical cellulitis because of their alkalinity, with tissue necrosis, ulceration or sloughing at the site of infiltration. Prompt elevation of the part, warmth and local injection of lidocaine or hyaluronidase are recommended to prevent sloughing of extravasated I.V. infusions.

OVERDOSAGE

Should alkalosis result, the bicarbonate should be stopped and the patient managed according to the degree of alkalosis present. 0.9% sodium chloride injection intravenous may be given; potassium chloride also may be indicated if there is hypokalemia. Severe alkalosis may be accompanied by hyperirritability or tetany and these symptoms may be controlled by calcium gluconate. An acidifying agent such as ammonium chloride may also be indicated in severe alkalosis. See WARNINGS and PRECAUTIONS.

DOSAGE & ADMINISTRATION

Sodium Bicarbonate Injection, USP is administered by the intravenous route.

In cardiac arrest, a rapid intravenous dose of one to two 50 mL vials (44.6 to 100 mEq) may be given initially and continued at a rate of 50 mL (44.6 to 50 mEq) every 5 to 10 minutes if necessary (as indicated by arterial pH and blood gas monitoring) to reverse the acidosis. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia.

In infants (up to two years of age), the 4.2% solution is recommended for intravenous administration at a dose not to exceed 8 mEq/kg/day. Slow administration rates and the 4.2% solution are recommended in neonates, to guard against the possibility of producing hypernatremia, decreasing cerebrospinal fluid pressure and inducing intracranial hemorrhage.

In less urgent forms of metabolic acidosis, Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-to-eight-hour period is approximately 2 to 5 mEq/kg of body weight — depending upon the severity of the acidosis as judged by the lowering of total CO₂ content, blood pH and clinical condition of the patient. In metabolic acidosis associated with shock, therapy should be monitored by measuring blood gases, plasma osmolality, arterial blood lactate, hemodynamics and cardiac rhythm. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid-base status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.

In general, it is unwise to attempt full correction of a low total CO₂ content during the first 24 hours of therapy, since this may be accompanied by an unrecognized alkalosis because of a delay in the readjustment of ventilation to normal. Owing to this lag, the achievement of total CO₂ content of about 20 mEq/liter at the end of the first day of therapy will usually be associated with a normal blood pH. Further modification of the acidosis to completely normal values usually occurs in the presence of normal kidney function when and if the cause of the acidosis can be controlled. Values for total CO₂ which are brought to normal or above normal within the first day of therapy are very likely to be associated with grossly alkaline values for blood pH, with ensuing undesired side effects.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

Do not use unless solution is clear and the container or seal is intact. Discard unused portion.

HOW SUPPLIED

7.5% SODIUM BICARBONATE INJECTION, USP is supplied in the following dosage forms.

NDC 51662-1463-1

7.5% SODIUM BICARBONATE INJECTION, USP 44.6mEq (0.9mEq/mL) 50mL SYR

HF Acquisition Co LLC, DBA HealthFirst

Mukilteo, WA 98275

PEDIATRIC 8.4% SODIUM BICARBONATE INJ., USP is supplied in the following dosage forms.

NDC 51662-1472-1

PEDIATRIC 8.4% SODIUM BICARBONATE INJ., USP 10mEq (1mEq/mL) 10mL SYR

HF Acquisition Co LLC, DBA HealthFirst

Mukilteo, WA 98275

Above items are also supplied in the following manufacture supplied dosage forms

Also supplied in the following manufacture supplied dosage forms

Sodium Bicarbonate Injection, USP is supplied in the following dosage forms:

List No.	Dosage Form	Conc. %	mg/mL (NaHCO ₃)	mEq/mL (Na ⁺)	mEq/mL (HCO ₃ [—])	mEq/Container size (mL)	mOsmol	pH
6637	Abboject® Syringe	8.4	84	1	1	50/50	2/mL	8.0 (7.0 to 8.5)
6625	Fliptop Vial	8.4	84	1	1	50/50	2/mL	7.8 (7.0 to 8.5)
4900	Abboject® Syringe (Pediatric)	8.4	84	1	1	10-Oct	2/mL	8.0 (7.0 to 8.5)
4916	Abboject® Syringe	7.5	75	0.9	0.9	44.6/50	1.79/mL	8.0 (7.0 to 8.5)
1594	LVP Glass Container	5	50	0.6	0.6	297.5/500	1190/liter	7.8 (7.0 to 8.5)
5534	Abboject® Syringe (Infant)	4.2	42	0.5	0.5	10-May	1/mL	8.0 (7.0 to 8.5)

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Revised: October, 2005

©Hospira 2005 EN-1064 Printed in USA

HOSPIRA, INC., LAKE FOREST, IL 60045 USA

ABBOJECT® is a trademark of the Abbott group of companies.

PRINCIPAL DISPLAY PANEL - 51662-1463-1 50mL SYR LABEL

7.5% Sodium Bicarbonate

Approx. mL



50 mL Single-dose

NDC 0409-4916-34

7.5% SODIUM BICARBONATE Injection, USP

44.6 mEq (0.9 mEq/mL) R_x only

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic. Discard unused portion.

1.79 mOsmol/mL (calc.) pH 8.0 (7.0 to 8.5)

RL-0056 (4/04)



(01) 0 030409 491634 7

Hospira, Inc., Lake Forest, IL 60045 USA



Packaging
Graphics Art

List **4916**

Commodity **RL-0056v2**

Label Control D-39B, Approval

Approved By

Date
*Not Valid Unless Final
Proofs Carry D-39B
Approval Signature

COLOR




PMS Black




White

BWR 2 MIL

PRINCIPAL DISPLAY PANEL - 51662-1463-1 CARTON LABEL



PRINCIPAL DISPLAY PANEL - 51662-1463-1 SERIALIZED CARTON LABELING



Inj., USP
44.6 mEq
(0.9 mEq/mL)

LifeShield™

Glass

ABBOJECT®
Unit of Use Syringe

with male luer lock
adapter and 18-Gauge
protected needle

Rx only

LOT 09-148-DK
EXP. 1SEP2021

← PRESS AND PULL TO

Hospira

Single-dose unit. Dis-
intra venous use. **Usual**
use the injection if it con-
to 25°C (68° to 77°F). [
Temperature.] To prev
needles should not be r
broken by hand.



RX ONLY

(01) 00351662146316

(17) 210901

(21) 221108728810

(10) 09148DK


See manufacturer's package insert
Distributed by HF Acquisition Co., LLC
Mukilteo, WA 98275




(01) 0



PRINCIPAL DISPLAY PANEL - 51662-1472-1 SYRINGE LABEL





Approx. mL (mEq)

8.4% Sodium Bicarbonate

0 1 2 3 4 5 6 7 8 9

10 mL Single-dose NDC 0409-4900-34

PEDIATRIC *Rx only*


8.4% SODIUM BICARBONATE *Hospira*

Inj., USP 10 mEq (1 mEq/mL)

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic. 2 mOsmol/mL (calc.). pH 8.0 (7.0 to 8.5).

Hospira, Inc., Lake Forest, IL 60045 USA RL-0047 (4/04)


(01) 0 030409 490034 6



Packaging Graphics Art

List **4900**

Commodity **RL-0047v2**




Label Control D-39B, Approval


Approved By


Date

***Not Valid Unless Final Proofs Carry D-39B Approval Signature**

COLOR SEPARATIONS

 **PMS Black**

 **PMS 117**

 **White**

BWR 2 MIL

PRINCIPAL DISPLAY PANEL - 51662-1472-1 CARTON LABEL

CAUTION: Liquid in glass.
Handle with care. Inspect vial
for damage prior to assembly.

Use Aseptic Technique

Do not assemble until ready to use.

1. Remove caps from vial and injector.

2. Insert vial into injector

without exerting excessive

force. Ensure that vial

and injector are properly

aligned. Gently rotate

vial clockwise (about

3 turns) until medication

enters needle. If resistance

is encountered, remove

vial and repeat

procedure.

3. To access green male luer lock

adapter, push yellow hood in and

then twist counterclockwise.

OR

To access needle, twist and pull

yellow hood clockwise to remove

hood and green adapter.

4. Apply gentle downward pressure

on vial to initiate liquid flow.

DO NOT APPLY EXCESSIVE

FORCE TO VIAL.

CA-2226

Printed in USA

Hospira, Inc., Lake Forest, IL 60045 USA

ABBOJECT™ is a trademark of the Abbott group of companies.

PEDIATRIC
8.4% SODIUM
BICARBONATE INJ., USP
10 mEq (1 mEq/mL)

Each mL contains sodium bicarbonate 84 mg, 1 mEq.
2 mEq/mL (ca. 1.1).
Medication, fluid path and needle are sterile and nonpyrogenic.
If caps and needle cover are undisturbed and package is intact.

BICARBONATE INJ., USP
8.4% SODIUM
10 mEq (1 mEq/mL)

10 mL NDC 0409-4900-34

PEDIATRIC
8.4% SODIUM
BICARBONATE
INJ., USP
10 mEq (1 mEq/mL)

lifeShield™

Glass
ABBOJECT™
Unit of Use Syringe
with male luer lock
adapter and 20-Gauge
protected needle

8.4%

Rx only

Hospira

OP EN

◀ **PRESS AND PULL TO OPEN**


10 mL NDC 0409-4900-34
PEDIATRIC
8.4% SODIUM
BICARBONATE INJ., USP
10 mEq (1 mEq/mL)

Single-dose unit. Discard unused portion. For
intravenous use. **Unit of Use:** See insert. Do not
use the injection if it contains precipitate. To prevent
needle-stick injuries, needles should not be
recapped, purposely bent or broken by hand. Store
at 20 to 25°C (68 to 77°F) [See USP Controlled Room
Temperature].



DO NOT PRINT DIE OUTLINE.
DC212207 For 46E and 095N use only

PRINCIPAL DISPLAY PANEL - 51662-1472-1 SERIALIZED LABELING



**8.4% SODIUM
BICARBONATE
INJ., USP**

10 mEq (1 mEq/mL)

LifeShield™

**Glass
ABBOJECT™**

Unit of Use Syringe

**with male luer lock
adapter and 20-Gauge
protected needle**

8.4%

Rx only

Single-dose unit. Discard unused intravenous use. **Usual dosage:** See use the Injection if it contains precipitate. needle-stick injuries, needles should be recapped, purposely bent or broken at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]



RX ONLY

**Insert
Co., LLC**



7.5% SODIUM BICARBONATE

7.5% sodium bicarbonate injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51662-1463(NDC:0409-4916)
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
SODIUM BICARBONATE (UNII: 8MDF5V39QO) (BICARBONATE ION - UNII:HN1ZRA3Q20, SODIUM CATION - UNII:LYR4M0NH37)	SODIUM BICARBONATE	75 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51662-1463-1	1 in 1 CARTON	01/29/2020	

1	50 mL in 1 SYRINGE; Type 1: Convenience Kit of Co-Package		
Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		01/29/2020	

PEDIATRIC 8.4% SODIUM BICARBONATE

pediatric 8.4% sodium bicarbonate injection, solution

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51662-1472(NDC:0409-4900)	
Route of Administration	INTRAMUSCULAR			
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
SODIUM BICARBONATE (UNII: 8MDF5V39QO) (BICARBONATE ION - UNII:HN1ZRA3Q20, SODIUM CATION - UNII:LYR4M0NH37)			SODIUM BICARBONATE	84 mg in 1 mL
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51662-1472-1	1 in 1 CARTON	01/29/2020	
1		10 mL in 1 SYRINGE; Type 1: Convenience Kit of Co-Package		
Marketing Information				
Marketing Category	Application Number or Monograph Citation		Marketing Start Date	Marketing End Date
unapproved drug other			01/29/2020	

Labeler - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Registrant - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Establishment

Name	Address	ID/FEI	Business Operations
HF Acquisition Co LLC, DBA HealthFirst		045657305	relabel(51662-1463, 51662-1472)